Northwestern Chemistry welcomes Katherine Lee (District I Director, ACS Board of Directors), hosted by NUBonD.
Discovery of IRAK4 Inhibitors by Fragment-Based Drug Design
Where do we start a drug discovery effort? In this talk, I will share a medicinal chemistry story from work at Pfizer in which a hit from a fragment screen of interleukin-1-associated kinase 4 (IRAK4) was optimized with structure-based design to discover potent, efficient IRAK4 inhibitors.
Biography: Katherine L. Lee is an expert in drug discovery, including structure-based and fragment-based drug design; a leader in portfolio strategy and business operations; and a strategic and scientific advisor on small and large molecule programs, most recently at Pfizer, Inc., in Cambridge, MA. She earned a B.S., summa cum laude, with Distinction in Chemistry, from Yale University and a Ph.D. in organic chemistry at MIT before completing a postdoc at the University of Texas at Austin. Her career in the pharmaceutical industry includes several years leading teams in medicinal chemistry and small molecule drug discovery, as well as in strategy and operations. Katherine has been District I Director in the American Chemical Society Board of Directors since 2019.
NUBonD
Email